Boston – It looks like being RAS week at the AACR-NCI-EORTC Triple meeting aka Targets19. Yesterday we explored the first-in-man data for the Mirati small molecule inhibitor, MRTX849, in KRASG12C mutant cancers that included lung and colon carcinomas.
In terms of aberrant activity in cancer, RAS comes in three different flavours, if you will – KRAS, NRAS, and HRAS.
After plenty of coverage of KRAS (and more yet to come!), it’s now time to turn our attention to a rather different oncogene driver and put HRAS to be in the spotlight. Here, we offer an updated look at the progress of Kura Oncology’s tipifarnib in squamous cell carcinomas of the head and neck (SCCHN) and assess the potential opportunity for approval in this setting.